Results 11 to 20 of about 1,370 (164)

OATP1A2 mediates Aβ1-42 transport and may be a novel target for the treatment of Alzheimer’s disease [PDF]

open access: yesFrontiers in Pharmacology
Alzheimer’s disease (AD) is a neurodegenerative disease with an unknown cause. Many studies have suggested that the imbalance between the clearance and accumulation of β-amyloid protein (Aβ) in the brain of AD patients is the main cause of AD development
Jinhua Wen   +4 more
doaj   +6 more sources

PDZK1 And NHERF1 Regulate the Function of Human Organic Anion Transporting Polypeptide 1A2 (OATP1A2) by Modulating Its Subcellular Trafficking and Stability [PDF]

open access: yesPLoS ONE, 2014
The human organic anion transporting polypeptide 1A2 (OATP1A2) is an important membrane protein that mediates the cellular influx of various substances including drugs. Previous studies have shown that PDZ-domain containing proteins, especially PDZK1 and
Fanfan Zhou, Michael Murray, Ling Zhu
exaly   +8 more sources

Human OAT1, OAT3, OAT4 and OATP1A2 Facilitate the Renal Accumulation of Ochratoxin A [PDF]

open access: yesPharmaceutics
Background/Objectives: Ochratoxin A (OTA) is a widespread foodborne mycotoxin linked to chronic kidney disease of unknown etiology. Despite evidence from animal models showing OTA accumulation in the kidney, the molecular mechanisms underlying its renal ...
Anish Mahadeo   +7 more
doaj   +4 more sources

FXR and Nrf2 Mediate the Effect of Carbon Ion Irradiation on Drug Transporter OATP1A2 in Cancer Cells [PDF]

open access: yesBiology
Organic anion transporting polypeptides (OATPs, gene symbol SLCO) are recognized as key factors in the absorption, distribution, and excretion of a wide range of endogenous and xenobiotic compounds, including many anti-neoplastic drugs.
Zichong Li   +5 more
doaj   +2 more sources

Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2) [PDF]

open access: yesJournal of Biological Chemistry, 2005
Organic anion-transporting polypeptide 1A2 (OATP1A2) is a drug uptake transporter known for broad substrate specificity, including many drugs in clinical use.
Wooin Lee   +7 more
openaire   +2 more sources

A novel fluorescence‐based functional assay for human OATP1A2 and OATP1C1 identifies interaction between third‐generation P‐gp inhibitors and OATP1A2

open access: yesThe FEBS Journal, 2019
Organic anion‐transporting polypeptide 1A2 (OATP1A2), expressed in the human blood–brain barrier, promotes drug uptake from the blood and hence can be exploited for central nervous system‐targeted drug delivery. The thyroid transporter OATP1C1, expressed in the choroid plexus and in astrocytes, is also a potential pharmacological target. Based on their
Éva Bakos   +6 more
openaire   +4 more sources

The Effects of N-Glycosylation on the Expression and Transport Activity of OATP1A2 and OATP2B1

open access: yesJournal of Pharmaceutical Sciences
Organic anion transporting polypeptide (OATP)1A2 and OATP2B1 have potential N-glycosylation sites, but their influence remains unclear. This study aimed to identify the N-glycosylation sites of OATP1A2/2B1 and investigate their impact on the expression and function of OATP1A2/2B1.
Hiroki Kataoka   +5 more
openaire   +5 more sources

HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms [PDF]

open access: yesPharmacogenetics and Genomics, 2010
OATP1B1 and OATP1B3 are major hepatic drug transporters whilst OATP1A2 is mainly located in the brain but is also located in liver and several other organs. These transporters affect the distribution and clearance of many endobiotics and xenobiotics and have been reported to have functional single nucleotide polymorphisms (SNPs).
Ruben C, Hartkoorn   +12 more
openaire   +3 more sources

Characterization of the membrane transporter OATP1A2 activity towards different classes of drugs [PDF]

open access: yes, 2016
Les transporteurs membranaires sont des éléments importants dans le devenir, l’efficacité, et la toxicité du médicament. Ils influencent la pharmacocinétique et la pharmacodynamie de ces derniers. Plusieurs interactions médicamenteuses observées cliniquement sont attribuables à la fois aux enzymes responsables du métabolisme des médicaments et aux ...
Lu, Jennifer
openaire   +2 more sources

Home - About - Disclaimer - Privacy